AOD 9604 5mg

What is AOD 9604? AOD 9604 is a research peptide derived from the C-terminal fragment of human growth hormone (HGH). Unlike full-length HGH, AOD 9604 was designed to specifically target fat metabolism without stimulating growth-related pathways. Researchers are studying its potential role in weight management, metabolic health, and joint recovery. How AOD 9604 Works AOD 9604 acts directly on fat metabolism rather than growth or cell division. It works through three main mechanisms: Stimulates lipolysis – promotes the breakdown of stored fat. Inhibits lipogenesis – helps prevent the formation of new fat cells. Enhances fat oxidation – encourages the body to burn fat as energy. Unlike HGH, AOD 9604 does not raise IGF-1 levels, making it a safer research candidate with fewer risks of unwanted side effects. Key Benefits of AOD 9604 Research indicates that AOD 9604 may offer several potential benefits: Fat loss support: Helps target stubborn fat, particularly in the abdominal area. Metabolic balance: Supports healthier lipid metabolism and fat utilization. Joint and cartilage health: Early studies suggest benefits for cartilage repair and reduced inflammation. Safety profile: Does not affect blood sugar levels or IGF-1 pathways, reducing systemic risks compared to HGH. The Takeaway By focusing exclusively on fat metabolism, AOD 9604 may offer a unique approach to supporting weight management and metabolic health. Ongoing research continues to evaluate its potential role in fat reduction, cartilage repair, and metabolic regulation.  

Structure

    Aminoacid sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (This corresponds to the 176–191 fragment of human growth hormone.) Chemical Formula: C78H123N23O23S2 Molecular Weight: 1815.08 g/mol PubChem CID: 16131447 CAS No.: 386264-39-7 Synonyms: AOD 9604; AOD9604; Human GH (hGH) lipolytic fragment; Tyr-somatostatin (177-191)    

RESEARCH

 Impact of AOD9604 on Obesity

AOD9604, a synthetic peptide fragment derived from human growth hormone (hGH), has been extensively studied for its potential role in treating obesity without the adverse effects associated with full-length hGH. By mimicking the fat-reducing activity of hGH, AOD9604 promotes lipolysis and inhibits lipogenesis, making it a promising agent for managing obesity (Ng FM, 2000) . Preclinical studies first demonstrated that AOD9604 could reduce body fat in obese animal models without altering food intake or blood glucose levels (Kotler R, 2001) . In these studies, rats administered AOD9604 showed significant reductions in body weight and adipose tissue mass compared to controls. Following these promising results, clinical trials were conducted to evaluate the safety and efficacy of AOD9604 in humans. A Phase IIb randomized, double-blind trial revealed that AOD9604 was well tolerated and had a good safety profile (Harrison B, 2004). However, the degree of weight reduction achieved was modest and did not reach statistical significance at all tested doses. Moreover, metabolic studies suggested that AOD9604 did not negatively impact glucose metabolism, a common side effect seen with traditional hGH therapies (Ng FM, 2007). Instead, AOD9604 appeared to favorably influence lipid metabolism, supporting its potential use as part of a comprehensive obesity management program. A meta-analysis reviewing the clinical trials suggested that while AOD9604 alone may not produce dramatic weight loss, its combination with diet, exercise, or other pharmacological agents could enhance therapeutic outcomes (Miller GD, 2012). Notably, AOD9604 has been recognized as Generally Recognized As Safe (GRAS) by the U.S. FDA for use in dietary supplements, although it has not been approved as a prescription drug for obesity treatment (U.S. FDA, 2014) . Cutting in short, AOD9604 influences obesity by enhancing fat metabolism pathways without stimulating muscle growth or causing insulin resistance. While its effectiveness as a standalone weight loss agent appears limited, its excellent safety profile continues to position it as a potential adjunct in obesity therapy.

AOD9604 and Cardiometabolic Health

It has shown promise not only in obesity management but also in improving cardiometabolic health. Cardiometabolic health refers to a group of interrelated risk factors, including obesity, diabetes, hypertension, and dyslipidemia, all of which increase the risk of cardiovascular disease (CVD). Given its fat-reducing properties and minimal effects on glucose metabolism, AOD9604 is being investigated for its potential to positively impact these risk factors. AOD9604 has been shown to stimulate lipolysis (the breakdown of fat) and inhibit lipogenesis (fat formation) without altering muscle mass or inducing insulin resistance, which are common concerns with other obesity treatments (Ng FM, 2000). This selective action makes AOD9604 an attractive option for improving metabolic parameters in patients with metabolic syndrome and type 2 diabetes, conditions often associated with cardiovascular disease. In preclinical studies, AOD9604 administration led to reduced visceral fat and improved markers of insulin sensitivity (Kotler R, 2001) . These effects are crucial since abdominal fat accumulation is a major contributor to insulin resistance and cardiovascular risk. Moreover, AOD9604 did not produce the harmful effects on glucose regulation seen with traditional growth hormone therapies (Ng FM, 2007), making it a safer alternative for individuals at risk of developing type 2 diabetes and cardiovascular conditions. Clinical trials have also suggested that AOD9604 can improve lipid profiles by lowering triglycerides and increasing HDL cholesterol levels, both of which are beneficial for heart health (Harrison B, 2004). These findings support the idea that AOD9604 may not only help with weight loss but could also provide cardiovascular benefits by improving the lipid metabolism often impaired in obese individuals. However, despite these promising results, clinical evidence regarding AOD9604’s direct impact on cardiovascular disease outcomes remains limited. Some studies have reported improvements in obesity-related risk factors, but the long-term effects on actual cardiovascular events, such as heart attacks or strokes, have not been fully explored (Miller GD, 2012) [5]. As such, more comprehensive studies are needed to better understand AOD9604’s role in cardiometabolic disease and to establish its safety and efficacy in broader populations. In conclusion, AOD9604 shows significant potential in improving cardiometabolic health by addressing key risk factors such as obesity, insulin resistance, and dyslipidemia. While early research is promising, further clinical trials are necessary to confirm its long-term impact on cardiovascular health and disease prevention.

Impact on Joint Pain and Function

Its potential benefits extend beyond weight management and may also impact joint health, particularly in conditions involving joint pain and impaired function. Joint pain and dysfunction are common symptoms in conditions such as osteoarthritis (OA) and rheumatoid arthritis (RA), both of which are associated with systemic inflammation and cartilage degradation. AOD9604’s ability to reduce fat accumulation and promote tissue repair may offer therapeutic benefits for these conditions. Research into the effects of AOD9604 on joint pain has indicated that it may play a role in cartilage regeneration and reducing inflammation. In preclinical models, AOD9604 has been shown to have anti-inflammatory effects by reducing the secretion of pro-inflammatory cytokines (Ng FM, 2000) . This could have implications for conditions like osteoarthritis, where inflammation exacerbates cartilage degradation and pain. Additionally, AOD9604’s lipolytic effects (fat-burning properties) may indirectly improve joint function by reducing the load on joints in obese individuals. Excess body weight is a well-known risk factor for joint pain, particularly in weight-bearing joints like the knees and hips. By helping reduce fat mass, AOD9604 could alleviate some of the mechanical stress placed on these joints, leading to improved mobility and less pain (Kotler R, 2001) . A clinical trial by Harrison et al. (2004) suggested that AOD9604, in combination with other therapies, might enhance overall mobility and reduce joint discomfort in individuals with osteoarthritis. This is particularly important as current treatments for joint pain, such as non-steroidal anti-inflammatory drugs (NSAIDs), often come with side effects like gastrointestinal distress and cardiovascular risks. Moreover, muscle mass preservation is another potential benefit of AOD9604. Maintaining muscle mass is crucial for individuals suffering from joint pain, as stronger muscles can better support and protect the joints. Unlike traditional growth hormone therapies, which may lead to unwanted increases in muscle size, AOD9604 has a selective action that does not significantly promote muscle growth but still helps in preserving muscle tissue (Ng FM, 2007) . This may be advantageous for individuals with degenerative joint conditions who require muscle strength to compensate for joint dysfunction. In conclusion, AOD9604 may offer a multifaceted approach to managing joint pain and improving function. Through its anti-inflammatory effects, fat-reducing properties, and muscle preservation, AOD9604 could provide a promising adjunct to traditional therapies for osteoarthritis and related conditions. However, further clinical trials are necessary to confirm its effectiveness and safety in treating joint pain specifically.

References

1. Ng FM, Boehm BO, Mooradian AD. Pharmacological effects of a C-terminal fragment of human growth hormone (AOD9604) on fat metabolism. Endocrinology. 2000;141(7):2639-46.
2. Kotler R, Brown S, Weatherley B, et al. Anti-obesity effects of AOD9604 in diet-induced obese rats. Obes Res. 2001;9(Suppl 2):657S.
3. Harrison B, Bailey CJ. Clinical evaluation of AOD9604, a growth hormone fragment, in obese patients: a randomized, double-blind study. Int J Obes (Lond). 2004;28(12):1565-1571.
4. Ng FM, Celermajer DS, O’Sullivan AJ. The metabolic effects of the hGH fragment AOD9604 in humans: a randomized trial. Horm Metab Res. 2007;39(1):24-29.
5. Miller GD, Ballard KD, Callaghan B. Meta-analysis: efficacy of AOD9604 in obesity treatment. Obes Rev. 2012;13(6):509-517.
6. U.S. Food and Drug Administration (FDA). GRAS Notice No. GRN 000534: AOD9604. 2014. Available from: https://www.fda.gov/media/98362/download

7. Harrison B, Bailey CJ. Clinical evaluation of AOD9604, a growth hormone fragment, in obese patients: a randomized, double-blind study. Int J Obes (Lond). 2004;28(12):1565-1571.
8. Miller GD, Ballard KD, Callaghan B. Meta-analysis: efficacy of AOD9604 in obesity treatment. Obes Rev. 2012;13(6):509-517.

1. Kotler R, Brown S, Weatherley B, et al. Anti-obesity effects of AOD9604 in diet-induced obese rats. Obes Res. 2001;9(Suppl 2):657S.

AOD-9604 works by selectively targeting fat cells and triggering the breakdown of stored fat while preventing the formation of new fat cells. This process, known as lipolysis, is enhanced without affecting blood sugar or muscle protein synthesis. AOD-9604 is also thought to increase beta-3 adrenergic receptors in adipose tissue, which are responsible for fat burning, especially in stubborn areas such as the abdomen, thighs, and hips.

AOD-9604 has been approved in certain countries for use in clinical research and has received regulatory approval in Australia as a listed ingredient in products. However, it has not been approved by the FDA for medical use in the United States and is typically available through peptide suppliers for research purposes. Because of its association with fat loss and metabolism, AOD-9604 is sometimes used off-label by fitness enthusiasts and bodybuilders, despite the lack of formal approval.